文献速递MDS 与骨髓增殖性肿瘤血栓与止血

妊娠期费城染色体阴性骨髓增殖性肿瘤的管理

How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy.
PubMed 文献 · Br J Haematol · 2020-03-09

本文综述妊娠期费城染色体阴性骨髓增殖性肿瘤(MPN)的诊疗管理。英国MPN妊娠发生率为3·2/100 000产妇/年,以原发性血小板增多症(ET)数据为主,文献提示母体血栓与出血、流产、子痫前期、胎儿生长受限(IUGR)、死胎及早产等显著母婴并发症。治疗选择包括阿司匹林、放血、低分子肝素(LMWH)和降细胞治疗,推荐由高危产科医生与血液科医生多学科联合管理。

要点

  • 育龄期MPN女性孕前应获得妊娠管理与结局的信息与咨询。
  • ET妊娠文献提示母体血栓、出血及不良胎儿结局风险显著。
  • 推荐产科与血液科多学科联合,从孕前规划管理至产后。

核心结论

  • 妊娠期费城染色体阴性MPN与显著母体及胎儿并发症相关,需多学科联合管理。

研究设计与样本

  • 综述类文章,汇总ET、PV、PMF妊娠相关文献并介绍国际中心本地实践与未来研究策略。

主要发现

  • 经典费城染色体阴性MPN合并发病率为6-9/100 000,发病高峰在50至70岁。
  • 英国MPN妊娠发生率为3·2/100 000产妇/年。
  • 15%的真性红细胞增多症(PV)患者诊断时年龄小于40岁。
  • ET妊娠文献提示母体血栓和出血、流产、子痫前期、IUGR、死胎和早产等并发症。
  • PV文献较稀疏但与ET妊娠结局一致,原发性骨髓纤维化(PMF)文献更少。

关键数值与推荐

  • 治疗选择包括阿司匹林、放血、低分子肝素(LMWH)和降细胞治疗。
  • 管理和治疗推荐常从其他促血栓疾病或从ET外推至PV和PMF。

临床怎么用

  • 育龄期MPN女性应接受未来妊娠管理与结局的信息与保证。
  • 从孕前规划到产后应由有高危妊娠经验的产科医生与血液科医生在多学科框架下联合照护。

局限性

  • 多数数据来自ET,PV文献较稀疏,PMF文献更少。
  • 管理和治疗推荐常为外推数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The combined incidence of classical Philadelphia-negative myeloproliferative neoplasm (MPN) is 6-9/100 000 with a peak frequency between 50 and 70 years. MPN is less frequent in women of reproductive age. However, for essential thrombocythaemia (ET) in particular there is a second peak in women of reproductive age and 15% of polycythaemia vera (PV) patients are less than 40 years of age at the time of diagnosis. Thus these diseases are encountered in women of reproductive potential and may be diagnosed in pregnancy or in women being investigated for recurrent pregnancy loss. The incidence of MPN pregnancies is 3·2/100 000 maternities per year in the UK. The majority of data regarding Philadelphia-negative MPNs relates to patients with ET, for which the literature suggests significant maternal morbidity and poor fetal outcome; specifically maternal thrombosis and haemorrhage, miscarriage, pre-eclampsia, intrauterine growth restriction (IUGR), stillbirth and premature delivery as summarised in the recent systematic review and meta-analysis in Blood, 2018, 132, 3046. The literature for PV is more sparse but increasing and is concordant with ET pregnancy outcomes. The literature regarding primary myelofibrosis (PMF) is even more scarce. Treatment options include aspirin, venesection, low molecular weight heparin (LMWH) and cytoreductive therapy. Data and management recommendations are often extrapolated from other pro-thrombotic conditions or from ET to PV and PMF. Women of reproductive age with a diagnosis of MPN should receive information and assurance regarding management and outcome of future pregnancies. From pre-conceptual planning to the post-partum period, women should have access to joint care from an obstetrician with experience of high-risk pregnancies and a haematologist in a multidisciplinary setting. This paper provides an update with regards to Philadelphia-negative MPN in pregnancy, details local practise in an internationally recognised centre for patients with MPN and outlines a future research strategy.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Robinson SE, Harrison CN. How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy. Br J Haematol. 2020. PMID: 32150650. doi:10.1111/bjh.16453

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。